Originally launched as as spin off from Ateriocyte Inc. (stem cell therapeutics) and DW Healthcare Partnera with $10mm financing, in October 2016, it was announced that Arteriocyte Medical Systems had been acquired by ISTO Holding on behalf of ISTO Technologies. Functioning as Isto Biologics, the new firm is structured to offer evidence-based solutions to expand its orthopedics, spine and functional-medicine product portfolios. With facilities in Cleveland OH, Hopkinton, MA, Rogers, MN and Salt Lake City, Utah, Arteriocyte Medical Systems, Inc., previously had been a medical device company, developing and marketing medical products to improve surgical outcomes in cardiac, orthopedic, and vascular surgeries. The company now offers autologous platelet separator system, an automated platelet separator system that is designed for physicians, clinicians, and technicians; and sterile disposables. In 2007 - soon after the creation of the firm, AMS had acquired Medtronic's Magellan platelet system. Arteriocyte went on to develop new treatment strategies that couple its novel cellular therapies with the innovative delivery platforms. ead product is the MAGELLAN® Autologous Platelet Separator. The firm's lead product, MAGELLAN® System provides surgeons the ability to separate peripheral blood or a combination of peripheral blood and bone marrow from a patient, for that patient, at bedside in approximately 15 minutes
